Vanguard Group Inc. Has $3.96 Billion Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Vanguard Group Inc. increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 20,131,734 shares of the medical research company’s stock after purchasing an additional 105,504 shares during the period. Vanguard Group Inc. owned about 11.09% of IQVIA worth $3,956,087,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the fourth quarter valued at $33,000. Avior Wealth Management LLC boosted its position in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the period. Lee Danner & Bass Inc. purchased a new position in IQVIA during the 4th quarter valued at about $44,000. Versant Capital Management Inc increased its holdings in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of IQVIA during the fourth quarter worth approximately $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 0.2 %

IQVIA stock opened at $186.35 on Tuesday. The firm has a market cap of $32.86 billion, a price-to-earnings ratio of 24.85, a P/E/G ratio of 1.99 and a beta of 1.50. The firm has a fifty day moving average price of $194.58 and a two-hundred day moving average price of $207.73. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $254.54. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on IQV shares. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Stifel Nicolaus cut their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. UBS Group lowered their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Robert W. Baird cut their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.